← All trials
NCT05212623
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2021
- Primary completion
- Jan 17, 2022
- Completion date
- Jun 16, 2022
- First posted
- Jan 28, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Changchun Institute of Biological Products Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.